{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-065613","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.805424+00:00","generated_at":"2026-05-22T08:43:17.064230+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Design Therapeutics Q1 net loss $17.7M; cash $229.7M funds into 2029","bullets":["R&D expenses $15.4M, G&A $5.0M for Q1 2025; net loss $17.7M.","Cash and securities $229.7M as of March 31, 2025; expected runway into 2029.","Phase 1 SAD trial ongoing for DT-216P2 (FA); MAD patient study planned mid-2025.","Favorable Phase 1 data for DT-168 (FECD); Phase 2 biomarker trial planned H2 2025.","Appointed Chris Storgard, M.D., as Chief Medical Officer in April 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-065613","json":"https://secwatch.observer/filing/0000950170-25-065613.json","markdown":"https://secwatch.observer/filing/0000950170-25-065613.md","text":"https://secwatch.observer/filing/0000950170-25-065613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017025065613/0000950170-25-065613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017025065613/dsgn-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:43:17.064230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}